Long-Term Diabetes Remission After Bariatric Surgery: 10-Year Follow-Up Study

Overview

This 10-year retrospective study evaluated diabetes remission and relapse rates in 427 patients with obesity undergoing metabolic and bariatric surgery (MBS). The findings demonstrate sustained type 2 diabetes remission in a substantial proportion of patients, with specific preoperative factors predicting long-term remission.

Background

Metabolic and bariatric surgery (MBS) is an established intervention for improving glycemic control and inducing remission of type 2 diabetes mellitus (T2DM) in patients with obesity. While short- and medium-term benefits of MBS on diabetes remission are well documented, long-term durability beyond 5 years remains less studied. Identifying predictors of sustained remission and understanding relapse patterns are critical for optimizing patient selection and management strategies.

Data Highlights

Key Findings

• Type 2 diabetes remission was sustained in a significant proportion of patients 10 years after MBS.
• Younger age, shorter diabetes duration, absence of insulin therapy, lower baseline fasting glucose and HbA1c, and higher C-peptide levels predicted long-term remission.
• Partial remission was defined by HbA1c 5.7–6.5% without pharmacologic therapy; complete remission by HbA1c <5.7% without therapy.
• Diabetes recurrence was identified by HbA1c ≥6.5% or need for reintroduction of anti-diabetic medications after remission.
• Patients undergoing Roux-en-Y gastric bypass had standardized biliopancreatic limb length of 70 cm.
• Exclusion criteria included gastric band surgery, re-operative bariatric procedures, and incomplete follow-up data.

Clinical Implications

MBS should be considered a durable therapeutic option for T2DM management in patients with obesity, especially those with favorable preoperative profiles. Long-term monitoring is essential to detect diabetes recurrence and guide ongoing management. Preoperative assessment of predictors can aid in patient selection and counseling regarding expected outcomes.

Conclusion

This decade-long follow-up study confirms that metabolic and bariatric surgery can achieve sustained remission of type 2 diabetes in a substantial subset of patients. Identification of clinical predictors enhances the ability to optimize patient outcomes and long-term diabetes control.

References

1. American Society for Metabolic and Bariatric Surgery & International Federation for the Surgery of Obesity and Metabolic Disorders, 2010-2013 -- Recommendations for MBS in T2DM
2. Systematic Review, 2017 -- Type 2 Diabetes Resolution Rates Post-MBS
3. Clinical Definitions of Diabetes Remission, 2019 -- Criteria for Partial and Complete Remission